The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

has accepted Libtayo (cemiplimab) for use on the National Health Service. This approval is for second-line monotherapy treatment of adults with recurrent or metastatic cervical cancer and disease ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for adults with recurrent or metastatic cervical cancer and disease progression ...

In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a second-line therapy for recurrent or advanced cervical cancer, regardless of PD-L1 expression status, ...

A recent CDC report further demonstrates the effectiveness of the HPV vaccine against cervical cancer. HPV is a sexually ...

Chemoradiation improves survival in cervical cancer patients, but benefits may decline after age 80, according to a study ...

The incidence of and mortality from cervical cancer are higher among rural-residing women versus their urban counterparts ...